

NUTRITIONAL SUPPLEMENT PROGRAM HALTS PROGRESSION OF EARLY CORONARY ATHEROSCLEROSIS DOCUMENTED BY ULTRAFAST COMPUTED TOMOGRAPHY

Matthias Rath, M.D.* and Aleksandra Niedzwiecki, Ph.D.

ABSTRACT: The aim of this study was to determine the effect of a defined nutritional supplement program on the natural progression of coronary artery disease. This nutritional supplement program was composed of vitamins, amino acids, minerals, and trace elements, including a combination of essential nutrients patented for use in the prevention and reversal of cardiovascular disease. The study was designed as a prospective intervention before-after trial over a 12 month period and included 55 patients (age 44-67) with various stages of coronary heart disease. Changes in the progression of coronary artery calcification before and during the nutritional supplement intervention were determined by Ultrafast Computed Tomography (Ultrafast CT). The natural progression rate of coronary artery calcification before the intervention averaged 44% per year. The progression of coronary artery calcification decreased on average 15% over the course of one year of nutritional supplementation. In a subgroup of patients with early stages of coronary artery disease, a statistically significant decrease occurred, and no further progression of coronary calcification was observed. In individual cases, reversal and complete disappearance of previously existing coronary calcifications were documented.

This is the first clinical study documenting the effectiveness of a defined nutritional supplement program in halting early forms of coronary artery disease within one year. The nutritional supplement program tested here should be considered an effective and safe approach to prevention and adjunct therapy of cardiovascular disease.

Key words: Coronary heart disease, Ultrafast Computed Tomography, nutritional supplements

INTRODUCTION

According to the World-Health Organization, over 12 million people die every year from heart attacks, strokes and other forms of cardiovascular disease (1). The direct and indirect costs for treat-

ment of cardiovascular disease are the single largest health care expense in every industrialized country of the world. Despite modest success in some countries in lowering the mortality rate from heart attacks and strokes, the cardiovascular epidemic is still expanding on a worldwide scale.

Current concepts of the pathogenesis of cardiovascular disease focus on elevated plasma risk factors damaging the vascular wall and thereby initiating atherogenesis and cardiovascular disease (2-4). Accordingly, drugs lowering chole-

* Corresponding author
Matthias Rath, M.D.
Postbus 405
NL-7600 AK Almelo
Fax: +31-546 533 103
www.rath.nl

terol and modulating other plasma risk factors have become a predominant therapeutic approach in the prevention of cardiovascular disease.

A new scientific rationale about the initiation of atherosclerosis and cardiovascular disease was proposed by one of us (5, 6). It can be summarized as follows: cardiovascular disease is primarily caused by chronic deficiencies of vitamins and other essential nutrients with defined biochemical properties, such as coenzymes, cellular energy carriers, and antioxidants (7, 8). Chronic depletion of these essential nutrients in endothelial and vascular smooth muscle cells impairs their physiological function. For example, chronic ascorbate deficiency, similar to early scurvy, leads to morphological impairment of the vascular wall and endothelial microlesions, histological hallmarks of early atherosclerosis (9-11). Consequently, atherosclerotic plaques develop as the result of an overcompensating repair mechanism comprising deposition of systemic plasma factors as well as local cellular responses in the vascular wall (5, 6). This repair mechanism is primarily exacerbated at sites of hemodynamic stress, explaining the predominantly local development of atherosclerotic plaques in coronary arteries and myocardial infarction as the most frequent clinical manifestation of cardiovascular disease.

Animal studies have confirmed this scientific rationale resulting in patents for the combination of ascorbate with other essential nutrients in the prevention and treatment of cardiovascular disease (12). Based on this patented technology, we have developed a nutritional supplement program, which was tested in this study in patients with coronary heart disease.

SUBJECTS AND METHODS

Subjects

A total of 55 patients, 50 men and 5 women, with documented coronary artery disease assessed by Ultrafast CT, were recruited for the study. The inclusion criterion was the availability of a high

quality Ultrafast CT scan from a previous visit to the Heart Scan facility in South San Francisco. At the beginning of the study each patient completed a comprehensive questionnaire, which was updated after six months and after 12 months. This questionnaire included medical history, previous cardiac events, and cardiovascular risk factors, as well as individual life style data. Specific questions related to the patients' regular diet, (such as strictly vegetarian diet, predominantly fruits and vegetables, predominantly meat, fish or poultry; the daily intake of different vitamins and other essential nutrients); and the frequency of physical exercise by the patient. The laboratory tests available documented a heterogeneous population with respect to plasma cholesterol and triglycerides. About half of the patients were taking different types of prescription medication, including calcium antagonists, nitrates, beta-blockers, and cholesterol-lowering drugs. Before entering the study, the patients were instructed not to change their diet or lifestyle other than adding the nutritional supplement program tested. Any changes were to be documented in their questionnaires. Compliance with the nutritional supplement program was monitored in the questionnaires, through telephone calls and during the control visits.

Composition and Administration of Nutritional Supplement Program

The following daily dosages of nutritional supplements were taken for a period of one year:

Vitamins: Vitamin C 2700 mg, Vitamin E(d-Alpha-Tocopherol) 600 IU, Vitamin A (as beta carotene) 7,500 IU, Vitamin B-1 (Thiamine) 30 mg, Vitamin B-2 (Riboflavin) 30 mg, Vitamin B-3 (as Niacin and Niacinamide) 195 mg, Vitamin B-5 (Pantothenate) 180 mg, Vitamin B-6 (Pyridoxine) 45 mg, Vitamin B-12 (Cyanocobalamin) 90 mcg, Vitamin D (Cholecalciferol) 600 IU.

Minerals: Calcium 150 mg, Magnesium 180 mg, Potassium 90 mg, Phosphate 60 mg, Zinc 30 mg, Manganese 6 mg, Copper 1500 mcg, Selenium 90 mcg, Chromium 45 mcg, Molybde-

num 18 mcg.

Amino acids: L-Proline 450 mg, L-Lysine 450 mg, L-Carnitine 150 mg, L-Arginine 150 mg, L-Cysteine 150 mg.

Coenzymes and other nutrients: Folic Acid 390 mcg, Biotin 300 mcg, Inositol 150 mg, Coenzyme Q-10 30 mg, Pycnogenol™ 30 mg, and Citrus Bioflavonoids 450 mg.

This nutritional supplement program is available world-wide from Health Now, Inc., San Francisco.

Monitoring of Coronary Artery Disease

The extent of coronary calcification was measured non-invasively with an Imatron C-100 Ultrafast CT scanner in the high resolution volume mode, using a 100- millisecond exposure time. ECG-triggering was used so that each image was obtained at the same point in the diastole, corresponding to 80% of the RR interval. In each scan, 30 consecutive images were obtained at 3 mm intervals beginning 1 cm below the carina and progressing caudally to include the entire length of the coronary arteries. The scans at study entry and after 6 and 12 months of the study included a second scan sequence of 30 images at 3 mm intervals across the entire heart. The 30 images of the second scan were taken between the 3 mm intervals of the first scan resulting in a

scanning of the heart at an interval of 1.5 mm. Total radiation exposure using this technique was <1 rad per patient (<.01 Gy).

The scan threshold was set at 130 Hounsfield units (Hu) for identification of calcified lesions. The minimum area to differentiate calcified lesions from CT artifact was 0.68 mm². The lesion score, also designated Coronary Artery Scanning (CAS) score, was calculated by multiplying the lesion area by a density factor derived from the maximal Hounsfield unit within this area (13). The density factor was assigned in the following way: 1 for lesions with a maximal density with 130-199 Hu, 2 for lesions with 200-299 Hu, 3 for lesions with 300-399 Hu and 4 for lesions > 400 Hu. The total calcium areas and CAS scores of each Ultrafast CT scan were determined by summing individual lesion areas or scores from the left main, left anterior descending, circumflex, and right coronary artery.

Several studies have confirmed an excellent correlation of the extent of coronary artery disease as assessed by Ultrafast CT scanning when compared to angiographic and histomorphometric methods (13-15). Considering the accuracy and the non-invasive approach, Ultrafast CT was the method of choice for an intervention study that included early, asymptomatic stages of coronary

Table 1. Clinical Characteristics of the Study Group as Assessed from Patient Questionnaire

	All Patients n = 55		Patients with Low CAS n = 21	
Age: 40-49	5	(9%)	4	(8%)
50-59	24	(44%)	8	(40%)
60-69	26	(47%)	9	(52%)
Current Smoker	4	(7%)	1	(5%)
Past Smoker	36	(65%)	12	(57%)
Diabetes	4	(7%)	0	(0%)
Thyroid Dysfunction	3	(5%)	1	(5%)
Previous Cardiac Events	5	(9%)	0	(0%)
Previous Angioplasty	2	(4%)	1	(5%)
Currently on Medication	27	(49%)	7	(33%)
Previous Vitamin Intake	36	(65%)	15	(71%)

artery disease.

Statistical Analysis

The growth rate of coronary calcifications was calculated as the quotient of the differences in the calcification areas or CAS scores between two scans divided by the months between these scans according to the formula $(\text{Area2}-\text{Area1}):(\text{Date2}-\text{Date1})$, or $(\text{CAS score2}-\text{CAS score1}):(\text{Date2}-\text{Date1})$ respectively. The data were analyzed using standard formulas for means, medians, and standard error of the means (SEM). Pearson's correlation coefficient was used to determine the association between continuous variables. One tailed Student t-test was used to analyze differences between mean values, with a significance defined at <0.05 . Progression of calcification was predicted by linear extrapolation. The distribu-


tion of the growth rate of CAS scores was described by a smooth curve resulting from a third order polynomial fit ($y = a + bx^3$, where $a = 0.9352959$, $b = 8.8235 \times 10^{-5}$).

RESULTS

The aim of this study was to determine the effect of a defined nutritional supplement program on the natural progression of coronary artery calcification particularly in its initial stages as measured by Ultrafast CT. We therefore evaluated the results of the entire study group ($n=55$) and of a subgroup of 21 patients with early coronary artery calcification, as defined by a CAS score of <100 .

Table 1 separately lists the characteristics of the study population assessed by the questionnaire for all patients and for a subgroup with early

Figure 1. Distribution of monthly increase in CAS scores in relation to CAS scores at study entry. The data represents all 55 patients individually. The calcification rate distribution pattern can be described by the polynomial curve: $y = a + bx^3$, where $a = 0.9352959$ and $b = 8.8235 \times 10^{-5}$.



coronary artery disease.


This is the first intervention study using Imatron's Ultrafast CT technology. One of the aims of this study was to determine the rate of natural progression of coronary calcium deposits *in situ*, without the intervention of the nutritional supplement program. **Figure 1** shows the distribution of the monthly progression of calcifications in the coronary arteries of all 55 patients in relation to their CAS score at study entry.

We found that the higher the CAS score was initially, without intervention, the faster the coronary calcification progressed. Accordingly, the

average monthly growth rate of coronary calcifications ranged from 1 CAS score per month in patients with early coronary heart disease to more than 15 CAS score per month in patients with advanced stages of coronary calcifications. The growth pattern of coronary calcifications can be described as a third order polynomial fit curve. The exponential shape of this curve signifies a first quantification of the aggressive nature of coronary atherosclerosis and emphasizes the importance of early intervention.

The changes in the natural progression rate of coronary artery calcification before the nutritional

Figure 2. Changes in the average monthly growth rate of calcified areas (2a, 2b) and CAS scores (2c, 2d) in all study participants (n=55) and in a subgroup of patients with initial stages of coronary calcifications (CAS score <100, n=21), before nutritional supplement intervention (-NS) and after one year of intervention (+NS). Data are mean $\pm$ SEM, asterisk indicates significance at $p < 0.05$ (one tailed t-test).




supplement program (-NS) and after one year on this program (+NS) are shown in **Figure 2**. The results are presented separately for the calcified area and the CAS score.

As presented in **Figure 2a**, the average monthly growth of calcified areas for all 55 patients decreased from 1.24 mm²/month (SEM $\pm$ 0.3) before the nutritional supplement program (-NS) to 1.05 mm²/month ($\pm$ 0.2) after one year

on this program (+NS). For patients with early coronary artery disease (**Figure 2b**), the average monthly growth of the calcified area decreased from 0.49 mm²/month ($\pm$ 0.16) before taking the nutritional supplements (-NS) to 0.28 mm²/month ($\pm$ 0.09) after one year on this program (+NS).

As shown in **Figure 2c**, the average monthly changes in the total CAS score (calcified area $\times$ density of calcium deposits) for all 55 patients

Figure 3. Actual progression of coronary calcification areas and CAS scores before and during one year of nutritional supplement intervention in a subgroup of patients with initial stages of coronary calcification (CAS <100), compared to calculated progression without intervention (dotted line). Each data point represents the mean value $\pm$ SEM.



had decreased after one year on the nutritional supplement program by 11%, from 4.8 CAS score/month (SEM $\pm$ 0.97) before the program (-NS) to 4.27 CAS score/month ($\pm$ 0.87) (+NS). In patients with early coronary artery disease (Figure 2d) the average monthly growth of the total CAS score decreased during the same time by as much as 65%, from 1.85 CAS score/month ($\pm$ 0.49) before the nutritional supplement program (-NS) to 0.65 CAS score/month ($\pm$ 0.36) on this program (+NS). The slow-down of the progression of coronary calcification during this nutritional supplement intervention for CAS scores of patients with early coronary artery disease was statistically significant ($p < 0.05$) (Figure 2d). For the other three sets of data the decrease of coronary calcifications with the nutritional supplement program was evident; however, largely due to the wide range of calcification values at study entry reflecting the different stages of coronary artery disease, it did not reach statistical significance.

It is noteworthy that the decrease in the CAS scores during intervention with nutritional supplements were more pronounced than for the calcified areas. This indicates a decrease in the density of calcium in addition to a reduction in the area of coronary calcium deposits during nutritional supplement intervention.

Ultrafast CT scans at the beginning of the study and after 12 months on the nutritional supplement program were complemented by a control scan after 6 months, allowing for additional insight into the time required for the nutritional supplements to exert their therapeutic effect. This additional evaluation was particularly important for early forms of coronary artery disease, because any therapeutic approach that can halt progression of early coronary calcification would ultimately prevent myocardial infarctions.

Figure 3 shows the average coronary calcification areas (Figure 3a) and total CAS scores (Figure 3b) for patients with early coronary artery disease measured during different scanning dates before and during the course of the study.

The actual coronary calcification values for areas and total CAS scores during nutritional supplement intervention are compared to the predicted values obtained from linear extrapolation of the growth rate without intervention. The letters A to D mark the different time points at which Ultrafast CT scans were performed. AB represents the changes in coronary calcification before intervention with nutritional supplement for the areas (Figure 3a) and CAS scores (Figure 3b). Accordingly, BC represents calcification changes during the first six months on the nutritional supplement program and CD changes during the second six months on the program. The calculated progression rate for coronary calcifications without therapeutic intervention by the nutritional supplement program is marked by a dotted line (B through F).

As seen in Figure 3a without the nutritional supplement program, the average area of coronary calcifications in patients with early coronary artery disease increased from 17.62 mm² ($\pm$ 1.0) at time point A to 23.05 mm² ($\pm$ 1.8) at time point B. Thus, the annual extension of calcified areas without intervention was assessed at 31%. At this progression rate, the average calcified area would reach 26.3 mm² after six months (point E) and 29.8 mm² after twelve months (point F). The nutritional supplement intervention, resulted in an average calcified area of 25.2 mm² ($\pm$ 2.2) after six months and of 27.0 mm² ($\pm$ 1.7) after 12 months, reflecting a 10% decrease compared to the predicted value.

Analogous observations were made for the total CAS score before and during the nutritional supplement program. Figure 3b shows that the CAS score before the nutritional supplement program increased by 44% per year, from 45.8 ($\pm$ 3.2) (point A) to 65.9 mm² ($\pm$ 5.2) (point B). At this progression rate the total CAS score, without the nutritional supplement program, would reach an average of 77.9 after six months (point E) and of 91 (point F) after twelve months. In contrast to this trend the actual CAS score values measured with the nutritional supplement program were


75.8 (± 6.2) after 6 months (point C) and 78.1 (± 5.1) after 12 months (point D). Thus, the progression of coronary calcification as determined by the total CAS scores decreased significantly during the second six months of nutritional supplement intervention (CD). The total score after twelve months on the nutritional supplement program was only 3% higher than after six months (CD), as compared to the projected increase of 17% (EF), indicating that during the second six months on the nutritional supplement program the process of coronary calcification has practically stopped.

Figure 4 shows the actual Ultrafast CT scans

of a 51 year old patient with early, asymptomatic, coronary artery disease. The patients' first Ultrafast CT scan was performed in 1993 as part of an annual routine check-up. The scan film revealed small calcifications in the left anterior descendens coronary artery as well as in the right coronary artery. The second CT scan was performed one year later at which time the initial calcium deposits had further increased. **Figure 4a** shows two Ultrafast CT scan images taken before the nutritional supplement program.

Subsequently, the patient started on the nutritional supplement program. About one year later the patient received control scans. At this time

Figure 4. Ultrafast CT scan images of a 51 year old patient with asymptomatic coronary artery disease before the nutritional supplement program (top row) and approximately one year later (bottom row). Calcium deposits in the left descending coronary artery and in the right coronary artery are visible as white areas.



point, coronary calcifications were not found (**Figure 4b**), indicating the natural reversal of coronary artery disease.

DISCUSSION

This is the first study that provides quantifiable data from in situ measurements about the natural progression rate of coronary artery disease. Although atherosclerotic plaques have a complex histomorphological composition, calcium dispersion within these plaques has been shown to be an excellent marker for their advancement (11, 13). Our study determined that the calcified vascular areas expand at a rate between 5 mm² (early atherosclerotic lesions) and 40 mm² (advanced atherosclerotic lesions). Before the nutritional supplement program the average annual increase of total coronary calcification was 44% (**Figure 1**). Considering the exponential increase of coronary calcification, it is evident that the control of cardiovascular disease has to focus on early diagnosis and early intervention.

Today, the diagnostic assessment of individual cardiovascular risk is largely confined to the measurement of plasma cholesterol and other risk factors with little correlation to the extent of atherosclerotic plaques. More accurate methods, such as coronary angiography, are confined to advanced, symptomatic, stages of coronary artery disease. Ultrafast CT provides the diagnostic option to quantify coronary artery disease non-invasively in its early stages (14, 15).

The most important finding of this study is that coronary artery disease can be effectively prevented and treated by natural means. This nutritional supplement program was able to decrease the progression of coronary artery disease within the relatively short time of one year, irrespective of the stage of this disease. Most significantly, in patients with early coronary calcifications, this nutritional supplement program was able to essentially stop its further progression. In individual cases with small calcified deposits, nutritional supplement intervention led to their complete disappearance (**Figure 4**).

We postulate that the nutritional supplement

program tested in this study initiates the reconstitution of the vascular wall. Restructuring of the vascular matrix is facilitated by several nutrients tested, such as ascorbate (vitamin C), pyridoxine (vitamin B-6), L-Lysine, and L-proline, as well as the trace element copper. Ascorbate is essential for the synthesis and hydroxylation of collagen and other matrix components (16-18), and can be directly and indirectly involved in a variety of regulatory mechanisms in the vascular wall from cell differentiation to distribution of growth factors (19, 20). Pyridoxine and copper are essential for the proper cross-linking of matrix components (8). L-Lysine and L-proline are important substrates for the biosynthesis of matrix proteins; they also competitively inhibit the binding of lipoprotein(a) to the vascular matrix, facilitating the release of lipoprotein(a) and other lipoproteins from the vascular wall (5, 12, 21). Ascorbate and α -tocopherol have been shown to inhibit the proliferation of vascular smooth muscle cells (22-24). Moreover, tocopherols, beta-carotene, ascorbate, selenium and other antioxidants scavenge free radicals and protect plasma constituents, as well as vascular tissue, from oxidative damage (25, 26). In addition, nicotinate, riboflavin, pantothenate, carnitine, coenzyme Q-10, as well as many minerals and trace elements, function as cellular cofactors in form of NADH, NADPH, FADH, Coenzyme A and other cellular energy carriers (8). The results of this study confirm that maintaining the integrity and physiological function of the vascular wall is the key therapeutic target in controlling cardiovascular disease. This also corroborates early angiographic findings that supplemental vitamin C may halt the progression of atherosclerosis in femoral arteries (27).

These conclusions are even more relevant since deficiencies of essential nutrients are common (28, 29). Moreover, many epidemiological and clinical studies have already documented the benefits of individual nutrients in the prevention of cardiovascular disease (30-35). Compared to

the high dosages of vitamins used in some of these studies the amounts of nutrients used in this study are moderate, indicating the synergistic effect of this program.

In this context, it seems appropriate to critically review some of the approaches currently used in the primary and secondary prevention of cardiovascular disease, including the extensive use of cholesterol-lowering drugs. An intervention study including lovastatin was performed with a highly selected group of hyperlipidemic patients, representing only an extremely narrow fraction of a normal population (36). More recently, the reduction of myocardial infarctions and other cardiac events in patients taking simvastatin, led to recommendations for its long-term use even by normolipidemic patients (37). However, because of their potential side-effects, the recommended use of these drugs has now been restricted to patients at high short term risk for coronary heart disease (38).

Similarly, certain natural approaches to prevention of cardiovascular disease deserve a critical review. A program of rigorous diet and exercise claims to be able to reverse coronary heart disease (39). However, the published study does not provide compelling evidence documenting the regression of coronary atherosclerosis. Thus, the improved myocardial perfusion shown in that study was likely the result of the physical training program, leading to an increased ventricular ejection fraction and an increased coronary perfusion pressure.

Considering the urgent need for effective and safe public health measures towards the control of cardiovascular disease, the validity of this study is of particular importance. In light of this, the following study elements are noteworthy:

1. The patients in this study served as their own controls before and during nutritional supplement intervention, thereby minimizing undesired co-variables such as age, gender, genetic predisposition, diet or medication.
2. Ultrafast CT has been extensively validated to assess the degree of coronary atherosclerosis, and it allowed quantification of coronary atherosclerotic plaques in situ (13-15). This diagnostic technique also minimizes errors as they occur in angiography studies in which vasospasms, formation or lysis of thrombi, and other events cannot be differentiated from progression or regression of atherosclerotic plaques. Moreover, Ultrafast CT provides valuable information about the morphological changes during progression and regression of atherosclerotic plaques, by quantifying not only the area of coronary calcifications but also their density. Furthermore, the automatic CT measurements of coronary calcifications eliminates human error in the evaluation of the data.

In summary, the results of this study imply that coronary heart disease is a preventable and essentially reversible condition. This study documents that coronary artery disease could be halted in its early stages by following this nutritional supplement program. These results were achieved within one year, suggesting that additional therapeutic benefits in patients with advanced coronary artery disease can be obtained by an extended use of this program. The continuation of this study is currently under way to document these effects. This nutritional supplement program signifies an effective and safe approach for the prevention and adjunct therapy of cardiovascular disease. This study should encourage public health policy makers and health care providers to redefine health strategies towards the control of cardiovascular disease.

ACKNOWLEDGMENTS

We are grateful to Jeffrey Kamradt from Health Now Inc. for his dedicated help in coordinating this study; Douglas Boyd Ph.D., Lew Meyer Ph.D., and Dale Grant from Imatron/HeartScan., South San Francisco, for helping to

plan the study and providing the HeartScan facility; Lauranne Cox, Susan Brody, and Tom Caruso for their collaboration in conducting the heart scans; Dr. Roger Barth and Bernard Murphy for their assistance in planning the study, and to Martha Best for her secretarial assistance.

NOTE

This publication was originally submitted to the *Journal of the American Medical Association (JAMA)* on August 5, 1996 and referred to Charles B. Clayman, MD Contributing Editor of *JAMA*, by Editor in Chief, George D. Lundberg, MD. In his letter dated August 23, 1996, Dr. Clayman rejected publication of this paper without further review. We immediately submitted our manuscript to the *Journal of Applied Nutrition* whose reviewers understood the implications of this study for human health and accepted it for publication without delay.

REFERENCES

- World Health Statistics, World Health Organization, Geneva, 1994.
- Brown MS, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. *Scientific American* 1984;251:58-66.
- Steinberg D, Parthasarathy S, Carew TE, Witztum JL. Modifications of low-density lipoprotein that increase its atherogenicity. *N Engl J Med*. 1989;320:915-924.
- Ross R. The pathogenesis of atherosclerosis-an update. *N Engl J Med*. 1986;314:488-500.
- Rath M, Pauling L. A unified theory of human cardiovascular disease leading the way to the abolition of this diseases as a cause for human mortality. *J Ortho Med*. 1992;7:5-15.
- Rath M, Pauling L. Solution to the puzzle of human cardiovascular disease: Its primary cause is ascorbate deficiency, leading to the deposition of lipoprotein(a) and fibrinogen/fibrin in the vascular wall. *J Ortho Med*. 1991;6:125-134.
- Rath M. Reducing the risk for cardiovascular disease with nutritional supplements. *J Ortho Med* 1992;3:1-6.
- Stryer L. *Biochemistry*, 3rd ed. New York: W.H. Freeman and Company; 1988.
- Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. *Atherosclerosis (Suppl.)* 1989;9:1-19-32.
- Constantinides P. The role of arterial wall injury in atherogenesis and arterial thrombogenesis. *Zentralbl allg Pathol pathol Anat*. 1989;135:517-530.
- Stolman JM, Goldman HM, Gould BS. Ascorbic acid in blood vessels. *Arch Pathol*. 1961;72:59-68.
- US Patent #5,278,189.
- Agatston AS, Janowitz WR, Kaplan G, Gasso J, Hildner F, Viamonte M. Ultrafast computed tomography—detected coronary calcium reflects the angiographic extent of coronary arterial atherosclerosis. *Am J Cardiology*. 1994;74:1272-1274.
- Budoff MJ, Georgiou D, Brody A, et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease. *Circulation*. 1996; 93:898-904.
- Mautner SI, Mautner GC, Froehlich J, et al. Coronary artery disease: prediction with in vitro electron beam CT. *Radiology*. 1994;192:625-630.
- Murad S, Grove D, Lindberg KA, Reynolds G, Sivarajah A, Pinnell SR. Regulation of collagen synthesis by ascorbic acid. *Proc Natl Acad Sci*. 1981;78:2879-2882.
- De Clerck YA, Jones PA. The effect of ascorbic acid on the nature and production of collagen and elastin by rat smooth muscle cells. *Biochem J*. 1980;186:217-225.
- Schwartz E, Bienkowski RS, Coltoff-Schiller B, Goldfisher S, Blumenfeld OO. Changes in the components of extracellular matrix and in growth properties of cultured aortic smooth muscle cells upon ascorbate feeding. *J Cell Biol*. 1982;92:462-470.
- Francheschi RT. The role of ascorbic acid in mesenchymal differentiation. *Nutr Rev*. 1992;50:65-70.
- Dozin B, Quatro R, Campanile g, Cancedda R. In vitro differentiation of mouse embryo chondrocytes: requirement for ascorbic acid. *Eur J Cell Biol*. 1992;58:390-394.
- Trieu VN, Zioncheck TF, Lawn RM, McConathy WJ. Interaction of apolipoprotein(a) with apolipoprotein B-containing lipoproteins. *J Biol Chem*. 1991; 226:5480-5485.
- Boscoboinik D, Szewczyk A, Hensley C, Azzi A. Inhibition of cell proliferation by α -tocopherol. Role of protein kinase C. *J Biol Chem*. 1991; 266:6188-6194.
- Ivanov V, Niedzwiecki A. Direct and extracellular matrix mediated effects of ascorbate on vascular smooth muscle cells proliferation. 24th AAA (Age) and 9th Am Coll Clin

- Gerontol Meeting, Washington DC, 1994;Oct14-18.
24. Nunes GL, Sgoutas DS, Redden RA, Sigman SR, Gravanis MB, King SB, Berk BC. Combination of vitamins C and E alters the response to coronary balloon injury in the pig. *Arteriosclerosis, Thrombosis and Vascular Biology*. 1995; 15:156-165.
25. Retsky KL, Freeman MW, Frei B. Ascorbic acid oxidation product(s) protect human low density lipoprotein against atherogenic modification. Anti- rather than prooxidant activity of vitamin C in the presence of transition metal ions. *J Biol Chem*. 1993;268:1304-1309.
26. Sies H, Stahl W. Vitamins E and C, beta-carotene and other carotenoids as antioxidants. *Am J Clin Nutr*. 1995;62(Suppl);1315S-1321S.
27. Willis GC, Light AW, Gow WS. Serial arteriography in atherosclerosis. *Can Med Ass J*. 1954;71:562-568.
28. Levine M, Contry-Caritilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended daily allowance. *Proc Natl Acad Sci*. 1996;93:3704-3709.
29. Naurath HJ, Joosten E, Riezler R. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. *The Lancet*. 1995;346:85-89.
30. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. *Epidemiology*. 1992; 3: 194-202.
31. Riemersma RA, Wood DA, Macintyre CCA, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamin A, C, and E and carotene. *The Lancet*. 1991;337:1-5.
32. Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. *JAMA*. 1995; 273:1849-1854.
33. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. *JAMA*. 1996; 275:1893-1896.
34. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). *The Lancet*. 1996;347:781-786.
35. Heitzer T, Just H, Menzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. *Circulation*. 1996;94:6-9.
36. Brown BG, Albers JJ, Fisher LD, Schafer SM, Lin J-T, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med*. 1990;323:1289-1298.
37. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *The Lancet* 1994;344:1383-1389.
38. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. *JAMA*. 1996;275:55-60.
39. Gould KL, Ornish D, Scherwitz L, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. *JAMA* 1995;274:894-901.